JP2014503567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503567A5 JP2014503567A5 JP2013550833A JP2013550833A JP2014503567A5 JP 2014503567 A5 JP2014503567 A5 JP 2014503567A5 JP 2013550833 A JP2013550833 A JP 2013550833A JP 2013550833 A JP2013550833 A JP 2013550833A JP 2014503567 A5 JP2014503567 A5 JP 2014503567A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- quinazoline
- pyrrolo
- formula
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- -1 - alkyl Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ZXOFAHRGRROAQR-UHFFFAOYSA-N 1-(isocyanomethylsulfonyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1S(=O)(=O)C[N+]#[C-] ZXOFAHRGRROAQR-UHFFFAOYSA-N 0.000 claims 1
- SNFGHOGDCXZSGY-UHFFFAOYSA-N 2-(4-bromo-2-methoxyanilino)-n-(2,6-diethylphenyl)-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(Br)C=C1OC SNFGHOGDCXZSGY-UHFFFAOYSA-N 0.000 claims 1
- JPYAEEZHLANFOV-UHFFFAOYSA-N 2-(4-bromo-2-methoxyanilino)-n-(2,6-diethylphenyl)-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(Br)C=C1OC JPYAEEZHLANFOV-UHFFFAOYSA-N 0.000 claims 1
- HCUXMELTHAQYDN-MUUNZHRXSA-N 2-(4-bromo-2-methoxyanilino)-n-[(1s)-2-(1,3-dioxoisoindol-2-yl)-1-phenylethyl]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound COC1=CC(Br)=CC=C1NC1=NC=C(CCC2=C3N(C)C=C2C(=O)N[C@H](CN2C(C4=CC=CC=C4C2=O)=O)C=2C=CC=CC=2)C3=N1 HCUXMELTHAQYDN-MUUNZHRXSA-N 0.000 claims 1
- CQNXJSHIMDAHNX-UHFFFAOYSA-N 2-(dimethylamino)-8-methyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(N(C)C)=NC=C2CCC2=C1NC(C)=C2C(N)=O CQNXJSHIMDAHNX-UHFFFAOYSA-N 0.000 claims 1
- NKTVIWIDORBNHH-UHFFFAOYSA-N 2-(dimethylamino)-8-methyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(N(C)C)=NC=C2C=CC2=C1NC(C)=C2C(N)=O NKTVIWIDORBNHH-UHFFFAOYSA-N 0.000 claims 1
- RJGLNSNPZNKTGL-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C=1C=C(NC=2N=C3C=4N(C)C(C)=C(C(N)=O)C=4CCC3=CN=2)C(OC)=CC=1N1CCN(C)CC1 RJGLNSNPZNKTGL-UHFFFAOYSA-N 0.000 claims 1
- BWJORBLWBGOLQL-UHFFFAOYSA-N 2-amino-8-phenyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound N1C(C2=NC(N)=NC=C2C=C2)=C2C(C(=O)N)=C1C1=CC=CC=C1 BWJORBLWBGOLQL-UHFFFAOYSA-N 0.000 claims 1
- UXWNPSLXAXDXKK-UHFFFAOYSA-N 2-amino-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1CC2=CN=C(N)N=C2C2=C1C(C(N)=O)=CN2C UXWNPSLXAXDXKK-UHFFFAOYSA-N 0.000 claims 1
- KVWLHWMGSYRLAU-UHFFFAOYSA-N 2-amino-9-methyl-8-phenyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound NC(=O)C=1C=2CCC3=CN=C(N)N=C3C=2N(C)C=1C1=CC=CC=C1 KVWLHWMGSYRLAU-UHFFFAOYSA-N 0.000 claims 1
- OXBHOAOVRFUPJX-UHFFFAOYSA-N 2-amino-9-methyl-8-phenylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound NC(=O)C=1C2=CC=C3C=NC(N)=NC3=C2N(C)C=1C1=CC=CC=C1 OXBHOAOVRFUPJX-UHFFFAOYSA-N 0.000 claims 1
- CCYINSRXXFXUST-UHFFFAOYSA-N 2-methyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(C)=NC=C2CCC2=C1NC=C2C(N)=O CCYINSRXXFXUST-UHFFFAOYSA-N 0.000 claims 1
- YQUFJQISWIFZLH-UHFFFAOYSA-N 2-methylsulfanyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1NC=C2C(N)=O YQUFJQISWIFZLH-UHFFFAOYSA-N 0.000 claims 1
- QZODUKPIHBQCBB-UHFFFAOYSA-N 2-methylsulfanyl-9-piperidin-4-yl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1=2C3=NC(SC)=NC=C3CCC=2C(C(N)=O)=CN1C1CCNCC1 QZODUKPIHBQCBB-UHFFFAOYSA-N 0.000 claims 1
- ZWVHBACWMIHSNL-UHFFFAOYSA-N 2-methylsulfanyl-9-piperidin-4-ylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1=2C3=NC(SC)=NC=C3C=CC=2C(C(N)=O)=CN1C1CCNCC1 ZWVHBACWMIHSNL-UHFFFAOYSA-N 0.000 claims 1
- JCICCACMYITOCI-UHFFFAOYSA-N 2-methylsulfanyl-9-propan-2-yl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(C(C)C)C=C2C(N)=O JCICCACMYITOCI-UHFFFAOYSA-N 0.000 claims 1
- XHEYSFJJPSXTHP-UHFFFAOYSA-N 2-methylsulfanyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1NC=C2C(N)=O XHEYSFJJPSXTHP-UHFFFAOYSA-N 0.000 claims 1
- KGKDUDXNIIDOCV-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-6,9-dihydro-5h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1NC(C)=C2C(N)=O KGKDUDXNIIDOCV-UHFFFAOYSA-N 0.000 claims 1
- DGFIPMBMVVDMPR-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-9-propan-2-yl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(C(C)C)C(C)=C2C(N)=O DGFIPMBMVVDMPR-UHFFFAOYSA-N 0.000 claims 1
- UKHAILBNXALNFF-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-9h-pyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1NC(C)=C2C(N)=O UKHAILBNXALNFF-UHFFFAOYSA-N 0.000 claims 1
- IJFXPCHHRYCYMT-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-methylsulfanyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(CCO)C=C2C(N)=O IJFXPCHHRYCYMT-UHFFFAOYSA-N 0.000 claims 1
- MNTKEWDJIACGNK-UHFFFAOYSA-N 9-(2-hydroxyethyl)-8-methyl-2-methylsulfanyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2CCC2=C1N(CCO)C(C)=C2C(N)=O MNTKEWDJIACGNK-UHFFFAOYSA-N 0.000 claims 1
- LVYDNZIZBIQXIS-UHFFFAOYSA-N 9-(2-hydroxyethyl)-8-methyl-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1N(CCO)C(C)=C2C(N)=O LVYDNZIZBIQXIS-UHFFFAOYSA-N 0.000 claims 1
- JYCIIVNGEUKVMV-UHFFFAOYSA-N 9-(3-amino-2,2-dimethylpropyl)-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide;hydrochloride Chemical compound Cl.C12=NC(SC)=NC=C2C=CC2=C1N(CC(C)(C)CN)C=C2C(N)=O JYCIIVNGEUKVMV-UHFFFAOYSA-N 0.000 claims 1
- JYHABUQXZXZOLO-UHFFFAOYSA-N 9-ethyl-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C1=NC(SC)=NC2=C3N(CC)C=C(C(N)=O)C3=CC=C21 JYHABUQXZXZOLO-UHFFFAOYSA-N 0.000 claims 1
- UECMCGVVQAQYOJ-UHFFFAOYSA-N 9-methyl-2-methylsulfanylpyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound C12=NC(SC)=NC=C2C=CC2=C1N(C)C=C2C(N)=O UECMCGVVQAQYOJ-UHFFFAOYSA-N 0.000 claims 1
- CXMXBFQRJAIBDD-UHFFFAOYSA-N 9H-cyclohepta[d]pyrimidine-8-carboxamide Chemical compound N1=CN=CC2=C1CC(=CC=C2)C(=O)N CXMXBFQRJAIBDD-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- FRANNCVVJFQWOT-TXEJJXNPSA-N C1=2C3=NC(SC)=NC=C3C=CC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 Chemical compound C1=2C3=NC(SC)=NC=C3C=CC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 FRANNCVVJFQWOT-TXEJJXNPSA-N 0.000 claims 1
- BRAYMNJVFKIQLD-TXEJJXNPSA-N C1=2C3=NC(SC)=NC=C3CCC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 Chemical compound C1=2C3=NC(SC)=NC=C3CCC=2C(C(N)=O)=CN1[C@@H]1CC[C@H](N)CC1 BRAYMNJVFKIQLD-TXEJJXNPSA-N 0.000 claims 1
- VTSDHOBIBSBOEN-UHFFFAOYSA-N Cl.CSC1=NC2=C3C(=CC=C2C=N1)C(=CN3)C(=O)N Chemical compound Cl.CSC1=NC2=C3C(=CC=C2C=N1)C(=CN3)C(=O)N VTSDHOBIBSBOEN-UHFFFAOYSA-N 0.000 claims 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 claims 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 1
- GFPDONVWLDXBHG-UHFFFAOYSA-N NC1=NC=2C3=C(CCC2C=N1)C(=CN3C)C(=O)NC3=C(C=C(C=C3)N3CCN(CC3)C)OC Chemical compound NC1=NC=2C3=C(CCC2C=N1)C(=CN3C)C(=O)NC3=C(C=C(C=C3)N3CCN(CC3)C)OC GFPDONVWLDXBHG-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- ISJSUWAGGVIHDZ-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(C)CC2)C=C1OC ISJSUWAGGVIHDZ-UHFFFAOYSA-N 0.000 claims 1
- HRLWNUGLIWNXQQ-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCC(CC2)N2CCCC2)C=C1OC HRLWNUGLIWNXQQ-UHFFFAOYSA-N 0.000 claims 1
- ILEDQKOHCPIFFS-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[3-(dimethylamino)propyl-methylamino]-2-methoxyanilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N(C)CCCN(C)C)C=C1OC ILEDQKOHCPIFFS-UHFFFAOYSA-N 0.000 claims 1
- YXROSHBBKYVTDI-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyanilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(CCO)CC2)C=C1OC YXROSHBBKYVTDI-UHFFFAOYSA-N 0.000 claims 1
- LYFDXTJJPSDFMS-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyanilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(CCO)CC2)C=C1OC LYFDXTJJPSDFMS-UHFFFAOYSA-N 0.000 claims 1
- SWEYDUSNJPBSGO-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]-8,9-dimethyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCC(CC2)N(C)C)C=C1OC SWEYDUSNJPBSGO-UHFFFAOYSA-N 0.000 claims 1
- PTUKZCQTLIICLP-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]-9-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCC(CC2)N(C)C)C=C1OC PTUKZCQTLIICLP-UHFFFAOYSA-N 0.000 claims 1
- GKHAZTHWYXEFJA-UHFFFAOYSA-N n-(2,6-diethylphenyl)-9-(methoxymethyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-8-methyl-5,6-dihydropyrrolo[3,2-h]quinazoline-7-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=C(C)N(COC)C(C2=N3)=C1CCC2=CN=C3NC1=CC=C(N2CCN(C)CC2)C=C1OC GKHAZTHWYXEFJA-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- TYHCBIKGTCZFTK-UHFFFAOYSA-N quinazoline-7-carboxamide Chemical compound C1=NC=NC2=CC(C(=O)N)=CC=C21 TYHCBIKGTCZFTK-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152190.2 | 2011-01-26 | ||
| EP11152190 | 2011-01-26 | ||
| PCT/EP2012/050773 WO2012101032A1 (en) | 2011-01-26 | 2012-01-19 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203440A Division JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503567A JP2014503567A (ja) | 2014-02-13 |
| JP2014503567A5 true JP2014503567A5 (enExample) | 2015-03-05 |
| JP5925809B2 JP5925809B2 (ja) | 2016-05-25 |
Family
ID=45562287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550833A Active JP5925809B2 (ja) | 2011-01-26 | 2012-01-19 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
| JP2015203440A Active JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203440A Active JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8975267B2 (enExample) |
| EP (1) | EP2668190B1 (enExample) |
| JP (2) | JP5925809B2 (enExample) |
| CN (1) | CN103339134B (enExample) |
| BR (1) | BR112013018515B1 (enExample) |
| ES (1) | ES2602791T3 (enExample) |
| RU (1) | RU2591191C2 (enExample) |
| WO (1) | WO2012101032A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR112013008527A2 (pt) * | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| RU2591191C2 (ru) | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| DK3129374T3 (en) * | 2014-04-07 | 2019-04-08 | Netherlands Translational Res Center B V | (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| ITRM20150212A1 (it) * | 2015-05-15 | 2016-11-15 | Univ Degli Studi Di Palermo | 4,5,6,9-tetraidropirrolo[2',3':3,4] cicloepta[1,2-d] isossazoli, procedimento per la loro produzione e loro uso come antitumorali |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| CN105130980B (zh) * | 2015-09-09 | 2018-05-22 | 沈阳药科大学 | N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| ES2987501T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Métodos de tratamiento de cánceres pediátricos |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN114213421A (zh) * | 2017-04-01 | 2022-03-22 | 晟科药业（江苏）有限公司 | 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| EP3992196B1 (en) * | 2019-08-02 | 2023-12-13 | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. | 1h-[1, 2, 3]triazolo[4, 5-h] quinazoline compounds acting as protein kinase inhibitors |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE |
| IL294214B2 (en) | 2019-12-27 | 2026-04-01 | Schrodinger Inc | Cyclic compounds and methods for using them |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| CN114685520B (zh) * | 2020-12-25 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| JP2024505890A (ja) | 2021-01-26 | 2024-02-08 | シュレーディンガー， インコーポレイテッド | がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| KR20240096905A (ko) * | 2021-12-15 | 2024-06-26 | 신라젠(주) | 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물 |
| AU2022408915B2 (en) * | 2021-12-15 | 2026-05-14 | Sillajen, Inc. | Methods of treating neoplastic diseases |
| CN122003418A (zh) | 2023-09-11 | 2026-05-08 | 薛定谔公司 | 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115833A (en) | 1994-11-25 | 1998-10-27 | Zeneca Ltd | 6,6-Dihalo-3,3-dimethyl-5-hydroxy-7,7,7-trifluoroheptanoic acids and their alkyl esters useful as intermediates for insecticides and their preparation |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| WO2003070706A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
| EA010904B1 (ru) * | 2003-05-22 | 2008-12-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| US8207180B2 (en) | 2006-11-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | Tricyclic indoles and (4,5-dihydro) indoles |
| US8084621B2 (en) | 2006-12-04 | 2011-12-27 | Jiangsu Simcere Pharmaceutical R&D Co. Ltd. | 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof |
| HUE024105T2 (hu) * | 2006-12-21 | 2016-02-29 | Nerviano Medical Sciences Srl | Szubsztituált pirazolo-kinazolin származékok, eljárás azok elõállítására és kináz inhibitorként történõ alkalmazásuk |
| AU2008277676A1 (en) * | 2007-07-16 | 2009-01-22 | Novartis Ag | Heterocyclic compounds useful as MK2 inhibitors |
| EP2240029A4 (en) | 2008-01-07 | 2012-08-22 | Synta Pharmaceuticals Corp | COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES |
| US8546410B2 (en) * | 2008-05-05 | 2013-10-01 | Abbvie Inc. | Heteroaryl-fused macrocyclic pyrimidine derivatives |
| AU2009264431B2 (en) * | 2008-06-26 | 2013-11-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazolines |
| US8518930B2 (en) * | 2008-07-29 | 2013-08-27 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent |
| WO2010012733A1 (en) * | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | Use of a cdk inhibitor for the treatment of glioma |
| WO2010058006A1 (en) * | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor for the treatment of mesothelioma |
| US8580793B2 (en) * | 2009-03-20 | 2013-11-12 | Nerviano Medical Services S.R.L. | Use of kinase inhibitor for the treatment of thymoma |
| ES2660146T3 (es) * | 2009-04-29 | 2018-03-21 | Nerviano Medical Sciences S.R.L. | Sales del inhibidor de cdk |
| AR076784A1 (es) * | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
| CN102470136B (zh) * | 2009-07-29 | 2013-12-25 | 内尔维阿诺医学科学有限公司 | Plk 抑制剂的盐类 |
| ES2539972T3 (es) * | 2010-07-30 | 2015-07-07 | Nerviano Medical Sciences S.R.L. | Isoxazolo-quinazolinas como moduladores de la actividad de proteina cinasa |
| BR112013008527A2 (pt) * | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| RU2591191C2 (ru) | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
-
2012
- 2012-01-19 RU RU2013139353/04A patent/RU2591191C2/ru active
- 2012-01-19 BR BR112013018515-5A patent/BR112013018515B1/pt active IP Right Grant
- 2012-01-19 ES ES12702207.7T patent/ES2602791T3/es active Active
- 2012-01-19 CN CN201280006541.4A patent/CN103339134B/zh active Active
- 2012-01-19 US US13/980,168 patent/US8975267B2/en active Active
- 2012-01-19 JP JP2013550833A patent/JP5925809B2/ja active Active
- 2012-01-19 EP EP12702207.7A patent/EP2668190B1/en active Active
- 2012-01-19 WO PCT/EP2012/050773 patent/WO2012101032A1/en not_active Ceased
-
2015
- 2015-01-30 US US14/609,534 patent/US9309253B2/en active Active
- 2015-10-15 JP JP2015203440A patent/JP6118383B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016053042A5 (enExample) | ||
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| US11578054B2 (en) | Compounds useful as immunomodulators | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| RU2013139353A (ru) | Трициклические пирролопроизводные, способ их получения и их применение в качестве ингибиторов киназы | |
| JP6898868B2 (ja) | Ｈｐｋ１阻害剤およびそれを用いる方法 | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| US20240173307A1 (en) | Modulators of the integrated stress pathway | |
| JP2021512150A5 (enExample) | ||
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| KR20180017013A (ko) | K-Ras 조절제 | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| US12090149B2 (en) | SMAD3 inhibitors | |
| JP2016501251A (ja) | がんの治療のための新規二環フェニル−ピリジン／ピラジン | |
| CN106458930A (zh) | 2‑氨基嘧啶类化合物及其药物组合物和应用 | |
| JP2014503566A5 (enExample) | ||
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| WO2020010003A1 (en) | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS | |
| JP2022539208A (ja) | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 | |
| US10730878B2 (en) | Fused quinoline compounds as PI3K/mTOR inhibitors | |
| CN116635390A (zh) | 作为血清素1b受体调节剂的强效和选择性化合物 | |
| CN103002899A (zh) | 作为pi3k抑制剂用于治疗抗增殖障碍的哌嗪子基三嗪化合物 | |
| KR102939670B1 (ko) | Pdl1 체크포인트 억제제로서의 헤테로고리 면역조절제 | |
| CN121399105A (zh) | 杂芳族dhodh抑制剂 | |
| NZ787908A (en) | Modulators of the integrated stress pathway |